The FDA has removed a clinical hold on NUZ-001, an investigational therapy being developed by NuraZ Therapeutics for a rare neurological disorder. The hold had been in place since earlier this year after the agency requested additional preclinical safety data to support continued dosing in human trials.
NuraZ Therapeutics stated that the FDA lifted the hold following review of new nonclinical results and protocol amendments addressing safety-monitoring and dose-escalation procedures. NUZ-001 targets a key molecular pathway associated with neurodegenerative progression and is being evaluated in a Phase 1/2 clinical study. The trial, which had previously paused enrollment, will now resume patient recruitment.
Under the revised plan, investigators will continue to assess safety, pharmacokinetics, and early signs of therapeutic benefit. NuraZ emphasized that study modifications were made in alignment with FDA feedback to enhance patient oversight.
Clinical holds are typically imposed when regulators identify incomplete or concerning safety data. The lifting of the hold indicates that the FDA considers the company’s updates sufficient to ensure participant protection, allowing NuraZ Therapeutics to advance NUZ-001’s development into its next phase of clinical evaluation.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!